{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of CNI-Sparing Regimens in Kidney Transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to either a CNI-sparing regimen or a standard CNI-based regimen."
      },
      "Participants": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted among kidney transplant recipients (KTRs) with low-to-moderate immunological risk."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received a CNI-sparing regimen, while the control group received standard CNI-based therapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "To evaluate the impact of CNI-sparing regimens on long-term allograft function."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was allograft function at 12 months, assessed by estimated glomerular filtration rate (eGFR)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The analysis was conducted using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group demonstrated improved eGFR (mean difference = 5.2 mL/min/1.73 m\u00b2, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention group and 1% in the control group experiencing gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: N/A"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}